Other substances

Riboflavin

A flavin.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

1
 Supporting references
0
 Contradictory references
7
 AI-suggested references
0
 Clinical trials

General information

Riboflavin on PubChem

Synonyms

Vitamin B2

 

Structure image - Riboflavin

CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Spike protein ACE2 Small molecule In silico 		in silico 2.08

Predicted to inhibit the interaction between the SARS-CoV-2 spike protein domain S1 and the host ACE2 receptor.

 Aug/21/2020

AI-suggested references

Link Publication date
Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Oct/02/2021
Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology
Jun/26/2020
In silico detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using Molecular Docking, Molecular Dynamic simulation and ADMET profiling
May/19/2020
Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
May/29/2020
Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein
Oct/08/2021
Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure.
Nov/10/2020
Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study
Mar/10/2022
Export (.csv)